Gene Therapy Market

Gene Therapy Market Is Estimated To Witness High Growth Owing To Advancements In Genome Editing Technologies


Gene therapy involves modifying or manipulating genes in an individual’s cells so as to treat or prevent a genetic disease. Gene therapy holds promise in treating a number of common and rare genetic disorders by providing a normal copy of a gene to replace the function of a missing or defective gene. Over the years, scientists have made major advancements in the field of genome editing which has expanded the scope of gene therapy to treat a variety of medical conditions.

The global Gene Therapy Market is estimated to be valued at US$ 10.37 Bn in 2024 and is expected to exhibit a CAGR of 4.7% over the forecast period 2024 to 2030.

Gene therapy offers targeted approach to treat underlying cause of diseases like inherited disorders, certain types of cancer and chronic infections by replacement, modification or correction of defective genes. Many biopharmaceutical companies are actively investing in R&D to develop novel gene therapies and bring multiple gene therapy products in market which will aid the market growth.

Key Takeaways

Key players operating in the gene therapy market are Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US) among others.

The key opportunities in the gene therapy market include growth in funding for gene therapy research, rise in awareness about gene therapy, development of CAR T-cell therapies for cancer treatment and greater adoption of advanced gene editing technologies like CRISPR.

Advancements in gene therapy vectors, gene editing technologies and availability of pre-clinical and clinical stage pipelines have expanded the scope of therapies for inherited disorders, neurodegenerative diseases, cardiovascular diseases and various types of cancers.

Market drivers

Development of new gene therapies – Several clinical stage development pipelines of Adeno-associated virus (AAV) gene therapies for neuromuscular, ophthalmology and cardiovascular diseases will drive the market growth over the forecast period. Majority of gene therapies in late stage clinical trials are expected to receive regulatory approvals which will augment the market revenues. Established safety and efficacy data of gene therapies globally will accelerate their commercial adoption.

Current Challenges in Gene Therapy Market

The gene therapy market is still in a nascent phase of development and faces significant scientific, clinical, regulatory and commercial challenges. Some key challenges include:

– Safety concerns related to viral vectors used to deliver genes into cells. Vectors need to be very efficient at delivering genes without inducing adverse immune reactions or causing cancer.

– Complex manufacturing processes. Producing gene therapies at commercial scales requires sophisticated manufacturing capabilities which are still being established by most companies.

– High treatment costs. Gene therapies aim to provide a one-time cure but typically have price tags in the millions of dollars due to development costs and manufacturing complexities.

SWOT Analysis

Strength: Gene therapies have the potential to cure diseases at the genetic level in a single treatment. They offer longer lasting effects than traditional drugs.
Weakness: Current gene therapies have high costs of development and manufacturing. Safety risks also arise from viral vectors used for gene delivery.
Opportunity: Large markets exist for genetic diseases like muscular dystrophy that currently have no cure. New technologies could make gene therapies applicable to a wider range of diseases.

Threats: Significant competition exists from other novel drug classes. Regulatory approvals remain uncertain and safety issues could reduce patient and physician confidence.

Geographical regions of concentration

North America currently accounts for the largest share of the global gene therapy market, primarily driven by high adoption of gene therapy products and continuous growth in research funding and clinical trials in the US. Europe is the second largest market driven by major gene therapy hubs in Germany, France and UK.

Fastest growing region
The Asia Pacific region is poised to grow at the fastest rate over the forecast period in the global gene therapy market. This is due to rising healthcare investments, expanding base of biotech companies, and growing patient population in major countries like China and India. Collaboration between global drugmakers and local players will help drive regional market growth.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it